Table 2.
Real-world use of radium-223 in patients with metastatic castration-resistant prostate cancer.
| Patients treated with radium-223, n (%) | Survived <6 months (n = 264) | Survived <2 years (n = 775)a | Survived ≥2 years (n = 185) | All patientsb (N = 1180) |
|---|---|---|---|---|
| Monotherapy | 162 (61.4) | 446 (57.5) | 86 (46.5) | 654 (55.4) |
| Combination therapy | 92 (34.8) | 283 (36.5) | 79 (42.7) | 441 (37.4) |
| —Hormonal therapy | 82 (31.1) | 259 (33.4) | 75 (40.5) | 406 (34.4) |
| —Hormonal therapy + chemotherapy | 5 (1.9) | 12 (1.5) | 1 (0.5) | 15 (1.3) |
| —Chemotherapy | 4 (1.5) | 10 (1.3) | 1 (0.5) | 15 (1.3) |
| —Hormonal therapy + immunotherapy | 0 | 1 (0.1) | 1 (0.5) | 2 (0.2) |
| —Other | 1 (0.4) | 1 (0.1) | 1 (0.5) | 3 (0.3) |
| Missing | 10 (3.8) | 46 (5.9) | 20 (10.8) | 85 (7.2) |
| Injections receivedc | ||||
| 6 | 5 (1.9) | 264 (34.1) | 143 (77.3) | 543 (46.0) |
| 5 or 6 | 18 (6.8) | 349 (45.0) | 156 (84.3) | 654 (55.4) |
| 1–4 | 246 (93.2) | 426 (55.0) | 29 (15.7) | 525 (44.5) |
aIncludes the 264 patients with survival <6 months.
bFull analysis set, including patients censored before 2 years.
cRadium-223 should be given as 6 injections at 4-week intervals; one patient censored within 2 years received 7 injections.